Small molecule targets Env for endoplasmic reticulum-associated protein degradation and inhibits human immunodeficiency virus type 1 propagation

Journal of Virology

Volumn 83, Issue 19, 2009, Pages 10075-10084

  Jejcic, Alenka ^a   Daniels, Robert ^b   Goobar Larsson, Laura ^a   Hebert, Daniel N ^b   Vahlne, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; GLYCYLPROLYLGLYCINAMIDE; PROTEASOME; TRIPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ARTICLE; CELL MATURATION; CONTROLLED STUDY; DEGLYCOSYLATION; DRUG MECHANISM; DRUG TARGETING; ENDOPLASMIC RETICULUM; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STEADY STATE; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS PARTICLE;

ANTIVIRAL AGENTS; ENDOPLASMIC RETICULUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENES, ENV; HELA CELLS; HIV-1; HUMANS; MODELS, BIOLOGICAL; POLYSACCHARIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN DENATURATION; PROTEIN STRUCTURE, TERTIARY; SUBCELLULAR FRACTIONS; VIRUS ASSEMBLY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70349266012     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01700-08     Document Type: Article

References (39)

1. Abacioglu, Y. H., T. R. Fouts, J. D. Laman, E. Claassen, S. H. Pincus, J. P. Moore, C. A. Roby, R. Kamin-Lewis, and G. K. Lewis. 1994. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res. Hum. Retrovir. 10:371-381.
2. Abdurahman, S., A. Vegvari, M. Levi, S. Hoglund, M. Hogberg, W. Tong, I. Romero, J. Balzarini, and A. Vahlne. 2009. Isolation and characterization of a small antiretroviral molecule affecting HIV-1 capsid morphology. Retrovirology 6:34.
3. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291. (Pubitemid 16013975)
4. Ahner, A., and J. L. Brodsky. 2004. Checkpoints in ER-associated degradation: excuse me, which way to the proteasome? Trends Cell Biol. 14:474-478.
5. Andersson, E., P. Horal, A. Jejcic, S. Hoglund, J. Balzarini, A. Vahlne, and B. Svennerholm. 2005. Glycine-amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glycine-amide. Antimicrob. Agents Chemother. 49:40-44.
6. Balzarini, J., E. Andersson, D. Schols, P. Proost, J. Van Damme, B. Svennerholm, P. Horal, and A. Vahlne. 2004. Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH2). Int. J. Biochem. Cell Biol. 36:1848-1859.
7. Bendtsen, J. D., H. Nielsen, G. von Heijne, and S. Brunak. 2004. Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol. 340:783-795.
8. Broliden, P. A., K. Ljunggren, J. Hinkula, E. Norrby, L. Akerblom, and B. Wahren. 1990. A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization. J. Virol. 64:936-940. (Pubitemid 20032716)
9. Carmona, R., L. Perez-Alvarez, M. Munoz, G. Casado, E. Delgado, M. Sierra, M. Thomson, Y. Vega, E. Vazquez de Parga, G. Contreras, L. Medrano, and R. Najera. 2005. Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients. J. Clin. Virol. 32:248-253.
10. Clouse, K. A., D. Powell, I. Washington, G. Poli, K. Strebel, W. Farrar, P. Barstad, J. Kovacs, A. S. Fauci, and T. M. Folks. 1989. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J. Immunol. 142:431-438. (Pubitemid 19039959)
11. Daniels, R., S. Svedine, and D. N. Hebert. 2004. N-linked carbohydrates act as lumenal maturation and quality control protein tags. Cell Biochem. Biophys. 41:113-138.
12. Derdeyn, C. A., J. M. Decker, J. N. Sfakianos, X. Wu, W. A. O'Brien, L. Ratner, J. C. Kappes, G. M. Shaw, and E. Hunter. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367.
13. Devito, C., M. Levi, K. Broliden, and J. Hinkula. 2000. Mapping of B-cell epitopes in rabbits immunised with various gag antigens for the production of HIV-1 gag capture ELISA reagents. J. Immunol. Methods 238:69-80. (Pubitemid 30175987)
14. Dwek, R. A., T. D. Butters, F. M. Platt, and N. Zitzmann. 2002. Targeting glycosylation as a therapeutic approach. Nat. Rev. Drug Discov. 1:65-75.
15. Earl, P. L., B. Moss, and R. W. Doms. 1991. Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J. Virol. 65:2047-2055.
16. Ellgaard, L., and A. Helenius. 2003. Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell. Biol. 4:181-191.
17. Gomez, C., and T. J. Hope. 2005. The ins and outs of HIV replication. Cell Microbiol. 7:621-626.
18. Horal, P., W. W. Hall, B. Svennerholm, J. Lycke, S. Jeansson, L. Rymo, M. H. Kaplan, and A. Vahlne. 1991. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides. Proc. Natl. Acad. Sci. USA 88:5754-5758.
19. Kalkut, G. 2005. Antiretroviral therapy: an update for the non-AIDS specialist. Curr. Opin. Oncol. 17:479-484.
20. Kuritzkes, D. R. 2004. Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDS 18:259-273. (Pubitemid 38720317)
21. Land, A., D. Zonneveld, and I. Braakman. 2003. Folding of HIV-1 envelope glycoprotein involves extensive isomerization of disulfide bonds and conformation-dependent leader peptide cleavage. FASEB J. 17:1058-1067. (Pubitemid 36676392)
22. Lee, K., W. Tirasophon, X. Shen, M. Michalak, R. Prywes, T. Okada, H. Yoshida, K. Mori, and R. J. Kaufman. 2002. IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes Dev. 16:452-466. (Pubitemid 34165102)
23. Lee, R. J., C. W. Liu, C. Harty, A. A. McCracken, M. Latterich, K. Romisch, G. N. DeMartino, P. J. Thomas, and J. L. Brodsky. 2004. Uncoupling retrotranslocation and degradation in the ER-associated degradation of a soluble protein. EMBO J. 23:2206-2215.
24. Li, Y., L. Luo, D. Y. Thomas, and C. Y. Kang. 1994. Control of expression, glycosylation, and secretion of HIV-1 gp120 by homologous and heterologous signal sequences. Virology 204:266-278. (Pubitemid 24305339)
25. Li, Y., L. Luo, D. Y. Thomas, and C. Y. Kang. 2000. The HIV-1 Env protein signal sequence retards its cleavage and downregulates the glycoprotein folding. Virology 272:417-428. (Pubitemid 30480202)
26. Lu, M., S. C. Blacklow, and P. S. Kim. 1995. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:1075-1082.
27. McCune, J. M., L. B. Rabin, M. B. Feinberg, M. Lieberman, J. C. Kosek, G. R. Reyes, and I. L. Weissman. 1988. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 53:55-67. (Pubitemid 18104049)
28. Meusser, B., C. Hirsch, E. Jarosch, and T. Sommer. 2005. ERAD: the long road to destruction. Nat. Cell Biol. 7:766-772.
29. Nielsen, H., J. Engelbrecht, S. Brunak, and G. von Heijne. 1997. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng. 10:1-6. (Pubitemid 27073346)
30. Nielsen, H., and A. Krogh. 1998. Prediction of signal peptides and signal anchors by a hidden Markov model. Proc. Int. Conf. Intell. Syst. Mol. Biol. 6:122-130.
31. Otteken, A., and B. Moss. 1996. Calreticulin interacts with newly synthesized human immunodeficiency virus type 1 envelope glycoprotein, suggesting a chaperone function similar to that of calnexin. J. Biol. Chem. 271:97-103.
32. Schwartz, S., B. K. Felber, E. M. Fenyo, and G. N. Pavlakis. 1990. Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J. Virol. 64:5448-5456. (Pubitemid 20364537)
33. Semenova, E. A., C. Marchand, and Y. Pommier. 2008. HIV-1 integrase inhibitors: update and perspectives. Adv. Pharmacol. 56:199-228.
34. Smith, S. D., M. Shatsky, P. S. Cohen, R. Warnke, M. P. Link, and B. E. Glader. 1984. Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res. 44:5657-5660.
35. Su, J., E. Andersson, P. Horal, M. H. Naghavi, A. Palm, Y. P. Wu, K. Eriksson, M. Jansson, H. Wigzell, B. Svennerholm, and A. Vahlne. 2001. The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1. J. Hum. Virol. 4:1-7.
36. Su, J., M. H. Naghavi, A. Jejcic, P. Horal, Y. Furuta, Y. P. Wu, S. L. Li, W. W. Hall, L. Goobar-Larsson, B. Svennerholm, and A. Vahlne. 2001. The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication. J. Hum. Virol. 4:8-15.
37. Terwilliger, E., J. Proulx, J. Sodroski, and W. A. Haseltine. 1988. Cell lines that express stably env gene products from three strains of HIV-1. J. Acquir. Immune Defic. Syndr. 1:317-323.
38. Wu, Y., and T. J. Kipps. 1997. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J. Immunol. 159:6037-6043. (Pubitemid 127471540)
39. Ye, Y., H. H. Meyer, and T. A. Rapoport. 2001. The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature 414:652-656. (Pubitemid 33151262)